GW Pharmaceuticals PLC (GWPH) is expected to post its quarterly earnings on Feb. 26. Last week, GW Pharma saw its stock slide
Categories
Health Care
Amarin shares jump 14% on rumors over Novartis interest
Shares of Amarin Corp (AMRN) gained up to 14% during the regular trading hours on Friday as rumors of an acquisition once
Earnings preview: Immunomedics might deliver lower revenue for Q2
Immunomedics Inc. (IMMU) is scheduled to report second-quarter 2019 earnings results on Monday, February 25, after market close. The consensus estimates are
Immune Design stock more than triples as it gets acquired by Merck
Merck (MRK) announced today that it will acquire immunotherapy developer Immune Design (IMDZ) for $5.85 per share in cash for an approximate value
Agilent Technologies stock drops despite beating Q1 estimates
Agilent Technologies (A) stock dropped about 4% in the extended trading hours despite reporting upbeat Q1 results. The muted guidance sent the
Tilray resumes deal spree, signs fifth in 2 months
Tilray Inc. (TLRY) has taken the fusion spree seriously as a new deal has been signed to buy hemp food company Manitoba
Bausch Health’s stock rises after Q4 revenue beats estimates
Bausch Health Companies Inc. (BHC) topped revenue estimates for the fourth quarter of 2018, sending shares climbing by 2.8% in morning hours
Aurora Cannabis shuffles its board of directors
Aurora Cannabis (ACB) on Wednesday announced the shuffle to its board of directors for aligning the directors' experience and expertise with the
CVS Health reports mixed Q4 results; stock falls over 7%
CVS Health Corporation (CVS) reported better-than-expected earnings for the fourth quarter of 2018 but revenue fell short of estimates, sending the stock
Intercept stock surges on positive data from liver fibrosis drug study
Intercept Pharmaceuticals (ICPT) had surged about 25% in the pre-market session on Tuesday after the biopharma company announced positive topline results from
Medtronic beats Q3 estimates and raises full-year guidance
Medtronic plc (MDT) topped consensus estimates on revenue and earnings for the third quarter of 2019 and raised its earnings guidance for
CVS Health Q4 earnings preview: What to expect
CVS Health Corporation (CVS) is scheduled to report fourth-quarter earnings results before the regular trading hours on Wednesday, February 20. The retail
Earnings preview: Medtronic could benefit from innovation, global expansion in Q3
Medical technology company Medtronic (MDT) will be reporting financial results for the third quarter Tuesday before the market opens. Analysts’ consensus earnings
Canopy Growth misses Q3 estimates
Canopy Growth (TSX: WEED, NYSE: CGC) reported a loss of CAD0.38 and revenue of CAD83 million, which missed analysts' predictions. Analysts expected Canopy
Quest Diagnostics Q4 profit drops 50%, misses estimates
Quest Diagnostics (DGX) reported a 50% drop in earnings for the fourth quarter due to a decline in net revenues, higher costs
Earnings: Oncology unit drives AstraZeneca topline higher in Q4
AstraZeneca Plc (AZN) reported a 22% dip in earnings for the fourth quarter to 82 cents per share, weighed down higher costs.
Johnson & Johnson buys Auris Health to boost medical devices business
Establishing its foray into robotic health products, pharmaceutical giant Johnson & Johnson (JNJ) on Wednesday announced it was acquiring California-based Auris Health
Earnings: Teva Pharma shrinks Q4 losses, but revenue falls
Teva Pharma (TEVA) posted its fourth-quarter 2018 before the opening bell on Feb. 13. The generic drugmaker saw revenue slip 16% to $4.56
Exelixis tops bottom and topline targets for Q4, stock rises
Exelixis (EXEL) reported Q4 earnings of 37 cents per share and revenue of $228.6 million that beat analysts' views. Analysts had expected
Gilead’s credibility takes a hit on massive NASH-drug failure, rivals jump
Shares of Gilead Sciences (GILD) have tumbled 20% in the past 52 weeks on numerous reasons including weaker-than-expected quarterly results and a
Q3 Earnings Preview: Canopy Growth likely to continue its recent bullish momentum
Canopy Growth (TSX: WEED, NYSE: CGC) will release its financial results for the third fiscal quarter of 2019 after the markets close